Skip to main content
ELVN
NASDAQ Life Sciences

Enliven Therapeutics Finalizes Upsized $400M Public Offering at Discounted Price

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$45.47
Mkt Cap
$2.81B
52W Low
$14.785
52W High
$48.53
52W Position info
208% above low
Off High info
6.3% below high
Rel. Volume info
4.8× avg
Market data snapshot near publication time

ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (4.8× avg).

Summary

Enliven Therapeutics finalized an upsized public offering, raising $400 million at a discount to fund its clinical pipeline, following positive Phase 1 data.


Key Events · Financing and Capital Events · ELVN

  • Upsized Public Offering Finalized

    Enliven Therapeutics entered into an underwriting agreement for an upsized public offering, raising approximately $400 million in gross proceeds. This formalizes the offering previously announced as proposed or priced.

  • Offering Details

    The offering includes 8,933,334 shares of common stock at $37.50 per share and 1,733,333 pre-funded warrants at $37.499 per warrant. Underwriters have a 30-day option to purchase up to an additional 1,600,000 shares of common stock.

  • Significant Capital Raise

    The $400 million gross proceeds represent a substantial capital infusion for the clinical-stage biopharmaceutical company, providing critical funding for its operations and pipeline advancement.

  • Discounted Pricing

    The offering price of $37.50 per share/warrant is a notable discount of approximately 17.5% to the current stock price of $45.47.


Analysis · ELVN · Life Sciences

Enliven Therapeutics has finalized an upsized public offering, securing approximately $400 million in gross proceeds through the sale of common stock and pre-funded warrants. This significant capital raise, priced at a notable discount to the current market price, follows recent positive Phase 1 clinical data for its lead drug candidate, ELVN-001. The funding is crucial for advancing the company's pipeline and extending its cash runway, which is a critical development for a clinical-stage biopharmaceutical company.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELVN was trading at $45.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $14.79 to $48.53. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELVN - Latest Insights

ELVN
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $48.80 info
Change: +$4.01 (+9%) info
Market Cap: $3.591B info
ELVN
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $48.80 info
Change: +$4.01 (+9%) info
Market Cap: $3.591B info
ELVN
Oct 06, 2026, 11:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $42.39
Real-time Price: $48.80 info
Change: +$6.41 (+15%) info
Market Cap: $3.591B info
ELVN
Jun 24, 2026, 7:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.60
Real-time Price: $48.80 info
Change: +$1.20 (+3%) info
Market Cap: $3.591B info
ELVN
Jun 22, 2026, 8:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $45.37
Real-time Price: $48.80 info
Change: +$3.43 (+8%) info
Market Cap: $3.591B info